Chemistry of Psilocybin
Scientific information about psilocybin chemistry: chemical compounds, metabolism, pharmacokinetics, and testing methods.
Introduction: Understanding Psilocybin at the Molecular Level
Psilocybin is a naturally occurring tryptamine alkaloid found in over 200 species of fungi, most prominently in species of Psilocybe, Panaeolus, and Gymnopilus. Chemically, it is a phosphorylated indole — 4-phosphoryloxy-N,N-dimethyltryptamine — closely related to the neurotransmitter serotonin (5-hydroxytryptamine) in structure.
Despite sharing structural similarity with serotonin, psilocybin is not pharmacologically active on its own. It is a prodrug: the body must convert it into its active form, psilocin (4-hydroxy-N,N-dimethyltryptamine), before it can act on serotonin receptors in the brain. This conversion happens rapidly in the gut and liver via alkaline phosphatase enzymes that cleave the phosphate group from the 4-position of the indole ring.
Psilocin then acts as a partial agonist at 5-HT2A serotonin receptors, primarily in the prefrontal cortex, thalamus, and default mode network — the brain regions responsible for self-referential thought, perception filtering, and conscious experience. The disruption of normal signalling in these areas produces the characteristic perceptual, cognitive, and emotional effects of psilocybin.
The Main Alkaloids in Psilocybin Mushrooms
Psilocybin and psilocin are not the only psychoactive compounds in mushrooms. Several related alkaloids are present in varying concentrations:
| Compound | Chemical name | Typical concentration | Notes |
|---|---|---|---|
| Psilocybin | 4-phosphoryloxy-DMT | 0.1–2% of dry weight | Primary compound; prodrug converted to psilocin |
| Psilocin | 4-hydroxy-DMT | 0–0.5% of dry weight | Active form; unstable — oxidises to blue pigments |
| Baeocystin | 4-phosphoryloxy-NMT | 0.01–0.5% of dry weight | Possibly mildly active; pharmacology less studied |
| Norbaeocystin | 4-phosphoryloxy-tryptamine | Trace | Pharmacological significance unclear |
| Aeruginascin | 4-phosphoryloxy-TMT | Trace (some species) | May modulate experience; found in Inocybe spp. |
Psilocybin content varies significantly between species, individual specimens within a species, flush number, growing conditions, and drying method. Even within a single batch of mushrooms, potency can differ between the cap and stem, or between early- and late-harvest specimens. This natural variability is why dose accuracy matters and why starting conservatively with any new batch is essential.
The Prodrug Mechanism: Psilocybin Becomes Psilocin
Understanding the prodrug mechanism helps explain several practical aspects of psilocybin use:
- Why onset takes time: Psilocybin must reach the small intestine, be dephosphorylated by alkaline phosphatase, and then psilocin must be absorbed through the gut wall and cross the blood-brain barrier. This process takes 20–90 minutes depending on stomach contents, individual metabolism, and preparation method.
- Why lemon tek works: Citric acid at pH 2–3 can partially perform the dephosphorylation step before ingestion, presenting the gut with psilocin directly rather than psilocybin. This compresses onset time and increases the initial rate of psilocin absorption.
- Why psilocin is unstable: The 4-hydroxy group on psilocin is chemically reactive and prone to oxidation. When mushroom tissue is damaged, psilocin oxidises rapidly, forming the characteristic blue quinoid pigments. Psilocybin, protected by its phosphate group, is far more stable — explaining why properly dried mushrooms store for years while fresh mushrooms begin degrading within days.
- Why heat degrades preparations: Both psilocybin and psilocin can degrade at high temperatures. Psilocybin remains relatively stable below 85°C; psilocin is more sensitive. Mushroom tea should be prepared with water below 85°C, not boiling.
How Psilocin Acts on the Brain
Psilocin's primary pharmacological action is as a partial agonist at 5-HT2A serotonin receptors. These receptors are most densely concentrated in the prefrontal cortex and are integral to the default mode network (DMN) — the brain's self-referential, "mental chatter" system active during introspection, mind-wandering, and narrative thought about the self.
Psilocin binding at 5-HT2A receptors disrupts normal DMN activity, reducing the rigid, top-down filtering that ordinarily constrains perception. Brain imaging studies (fMRI) show increased connectivity between brain regions that do not normally communicate — a state associated with novel associations, ego softening, and altered time perception. This disruption of habitual cognitive patterns is thought to underlie psilocybin's therapeutic potential in conditions involving rigid, maladaptive thought patterns such as depression, OCD, and addiction.
Psilocin also acts on other serotonin receptor subtypes (5-HT2C, 5-HT1A) and has weak affinity for dopamine receptors, contributing to the full spectrum of effects including euphoria, nausea, and pupil dilation.
Why Psilocybin Does Not Cause Addiction
Unlike opioids, alcohol, nicotine, or stimulants, psilocybin does not produce dopaminergic reward signalling in the nucleus accumbens — the brain's primary reward/reinforcement circuit. There is no craving, compulsive seeking, or physical withdrawal associated with psilocybin. Compulsive use is extremely rare, and most users find that frequent use is self-limiting due to rapid tolerance (5-HT2A downregulation) and the demanding nature of the experience.
The World Health Organization and multiple national health agencies classify psilocybin as having low abuse potential and no physical dependence liability, though it remains legally controlled in most countries.
Chemistry Topics
Chemical Compounds
Dosing & Testing
Frequently Asked Questions
What is the difference between psilocybin and psilocin?
Psilocybin is the stable prodrug form found in mushrooms. It is pharmacologically inactive until metabolised by alkaline phosphatase enzymes in the gut and liver, which remove its phosphate group to produce psilocin. Psilocin is the active compound that crosses the blood-brain barrier and binds to serotonin receptors to produce psychedelic effects. Psilocin is chemically unstable (it oxidises to blue pigments) while psilocybin is stable and stored for years in properly dried mushrooms.
How does psilocybin affect serotonin receptors?
Psilocin (the active metabolite) acts as a partial agonist at 5-HT2A serotonin receptors, meaning it binds and activates the receptor but with less efficacy than full agonists. The most significant effects occur in the prefrontal cortex, where 5-HT2A activation disrupts the default mode network — the brain's self-referential processing system. This disruption produces the altered perception, ego-softening, and novel cognitive connections characteristic of psilocybin experiences.
What is the half-life of psilocybin and psilocin?
Psilocybin has a plasma half-life of approximately 160 minutes (about 2.5 hours). Psilocin, the active metabolite, has a shorter half-life of approximately 50 minutes, but is continuously replenished from remaining psilocybin in the bloodstream. Total psychedelic effects typically last 4–6 hours, after which plasma psilocin falls below the threshold for perceptible effects. Minor residual effects (altered mood, fatigue) may persist for several additional hours.
Why do psilocybin mushrooms turn blue when bruised?
The blue bruising reaction is caused by oxidation of psilocin. When mushroom tissue is damaged — bruised, cut, or dried — the enzyme psilocinase converts psilocybin to psilocin, which then reacts with atmospheric oxygen to form blue-coloured quinoid compounds structurally similar to melanins. The presence of bruising indicates psilocin-containing mushrooms but cannot be used to quantify potency. Not all psilocybin-containing species bruise visibly, and some non-psilocybin mushrooms produce similar blue reactions through different chemistry.
Does psilocybin show up on drug tests?
Standard 5-panel drug tests do not screen for psilocybin or psilocin — they test for cannabis, cocaine, amphetamines, opiates, and PCP. Specialised extended tests (NIDA-10, forensic panels) can detect psilocin metabolites in urine for approximately 24 hours after ingestion and in blood for up to 12 hours. Hair follicle testing can theoretically detect use for up to 90 days, though this is rarely used outside forensic contexts. Psilocybin does not produce false positives on standard immunoassay drug tests.
Is psilocybin toxic or harmful to the body at normal doses?
Psilocybin has extremely low acute toxicity. The estimated LD50 (the dose that would kill 50% of subjects) in animal studies is approximately 280 mg/kg body weight — roughly equivalent to a human consuming kilograms of dried mushrooms in one sitting. There are no documented human fatalities from psilocybin toxicity alone. The primary physical risks are cardiovascular (elevated heart rate and blood pressure during peak effects) and psychological (anxiety, paranoia). The main safety risks are behavioural: accidents, risky decisions, or psychological crises in vulnerable individuals.